Skip Navigation


Rheumatology Advance Access originally published online on September 9, 2008
Rheumatology 2008 47(11):1726-1727; doi:10.1093/rheumatology/ken334
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
47/11/1726    most recent
ken334v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Pradeep, D. J.
Right arrow Articles by Harris, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pradeep, D. J.
Right arrow Articles by Harris, C.
Related Collections
Right arrow Spondylarthropathies
Right arrow Pharmacology
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

LETTERS TO THE EDITOR

Switching anti-TNF therapy in ankylosing spondylitis

D. J. Pradeep1, A. C. Keat2, K. Gaffney1, A. Brooksby1, J. Leeder1 and C. Harris2

1Department of Rheumatology, Norfolk and Norwich University Hospital, Norwich, Norfolk and 2Arthritis Centre, Northwick Park Hospital, Harrow, Middlesex, UK

Correspondence to: J. Pradeep, Department of Rheumatology, East block, level 1, Norfolk and Norwich University Hospital, Norwich, Norfolk NR4 7UY, UK. E-mail: john.pradeep@nnuh.nhs.uk

The first 10% of the full text of this article appears below.

SIR, The introduction of anti-TNF drugs has revolutionized the management of ankylosing spondylitis (AS) [1] and the efficacy of these drugs has been confirmed in clinical trials [2–4]. However, a significant proportion of patients withdraw from treatment because of inadequate efficacy (IE) or adverse effects (AEs). Because there are significant differences between chemical structure of anti-TNF drugs and mechanism of action there is a rationale for switching in these circumstances. Data from patients with RA suggest that switching from one anti-TNF drug to . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?